Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133486 | 0.83 | NAAA (0.49) | EPHX2NAAANAMPTEPHX1ALDH1A1 | |
| SCHEMBL9508710 | 0.80 | ALDH1A1 (0.50) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL3741148 | 0.80 | HDAC6 (0.44) | EPHX2HDAC6ALDH1A1 | |
| SCHEMBL3744798 | 0.80 | HDAC6 (0.44) | EPHX2HDAC6ALDH1A1 | |
| SCHEMBL3200016 | 0.78 | NAAA (0.50) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL4137357 | 0.76 | NAAA (0.58) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL5268847 | 0.76 | NAAA (0.48) | NAAAEPHX1ALDH1A1HTTNPC1 | |
| SCHEMBL27376298 | 0.76 | NAAA (0.65) | EPHX2NAAAMLYCDALDH1A1HTT | |
| SCHEMBL4137732 | 0.75 | EPHX2 (0.81) | EPHX2EPHX1ALDH1A1HTTNPC1 | |
| SCHEMBL3399062 | 0.74 | POLQ (0.48) | HDAC6ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | EPHX2 4248/4885HDAC6 713/4885NAAA 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.